LTRN Lantern Pharma Inc. — earnings, filings & institutional moves

Price chart

Daily historical data with per-account defaults

Latest close

$2.93

Period return

-0.46 (-13.57%)

Volume

24.4K

2026-07-21O $2.97 H $3.03 L $2.87 C $2.93MA5 $2.95MA20 $3.52MA60 $3.23MA120 $2.84

6M · 125 barsYahoo Finance · USD2026-01-21 → 2026-07-21

Recent event timeline

Filings, earnings, research, and institutional changes — newest first

View all →

2026. 08. 12.Highin 22 days
다음 실적 발표 예정
예정된 실적 발표입니다. 일정과 시장 기대치를 확인하세요.
2025. 04. 02.MediumBUYlast year
Lake Street: Buy
US analyst rating / recommendation change.
2024. 04. 25.LowHOLD2 years ago
HC Wainwright & Co.: Neutral
US analyst rating / recommendation change.
2023. 08. 10.LowBUY3 years ago
EF Hutton: Buy
US analyst rating / recommendation change.
2023. 06. 27.LowBUY3 years ago
EF Hutton: Buy
US analyst rating / recommendation change.
2023. 05. 18.MediumHOLD3 years ago
HC Wainwright & Co.: Neutral
US analyst rating / recommendation change.
2023. 03. 21.LowBUY3 years ago
EF Hutton: Buy
US analyst rating / recommendation change.
2023. 02. 16.LowBUY3 years ago
EF Hutton: Buy
US analyst rating / recommendation change.
2022. 11. 01.MediumBUY4 years ago
EF Hutton: Buy
US analyst rating / recommendation change.
2022. 03. 11.LowBUY4 years ago
HC Wainwright & Co.: Buy
US analyst rating / recommendation change.

Recent earnings

Consensus vs. actual, and revenue trend

Earnings tab →

Research actions

Consensus PT $20 · 2 analysts

Research tab →

AI Brief (Premium)

Automated summary from public sources · not investment advice

Brief tab →

No AI brief generated yet. You can create one from the Brief tab.

Top institutions (13F)

Ranked by position value

Institutions tab →

Company info

Lantern Pharma Inc. focuses on the discovery and development of oncology drug in India. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1a clinical trial for the treatment of advanced or metastatic solid tumors, or unresectable or recurrent GBM, solid tumor, such as pancreatic, breast, bladder, and lung cancers, as well as glioblastoma and other central nervous system (CNS) cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma. The company also develops STAR-001, which is in preclinical development for the treatment of glioblastoma, brain metastases, atypical teratoid rhabdoid tumors, and several rare pediatric CNS cancers. In addition, it provides ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. The company has a strategic AI-driven collaboration with Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase inhibitor drug candidate XCE853 in novel and targeted cancer indications; a collaboration agreement with TTC Oncology, which focuses on the drug development of TTC-352 to treat patients with metastatic ER+ breast cancer; and a collaboration agreement with Actuate Therapeutics, Inc. that focuses on the development of compounds for use in the treatment of cancer and inflammatory diseases leading to fibrosis. The company was incorporated in 2013 and is headquartered in Dallas, Texas.

Lantern Pharma Inc.

Price chart

Recent event timeline

Recent earnings

Research actions

Top news

Key stats

Date	Firm	Analyst	Action	Rating change	Price target	Report
2025. 04. 02.	Lake Street	—	Initiate coverage	— → Buy	—	Lake Street: Buy
2024. 04. 25.	HC Wainwright & Co.	—	Maintain	— → Neutral	—	HC Wainwright & Co.: Neutral
2023. 08. 10.	EF Hutton	—	Maintain	Buy → Buy	—	EF Hutton: Buy
2023. 06. 27.	EF Hutton	—	Maintain	Buy → Buy	—	EF Hutton: Buy
2023. 05. 18.	HC Wainwright & Co.	—	Initiate coverage	— → Neutral	—	HC Wainwright & Co.: Neutral
2023. 03. 21.	EF Hutton	—	Maintain	— → Buy	—	EF Hutton: Buy